Clinical Trial Detail

NCT ID NCT04120454
Title Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab + Ramucirumab

Age Groups: adult senior

No variant requirements are available.